Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model

Journal of Translational Medicine

Walter T Lee²  Scott K Pruitt²  Douglas S Tyler²  Smita K Nair⁵  Enyu Ding³  Jens Dannull¹  Varun Reddy⁴  Chunrui Tan³ 

[1] Department of Surgery, Duke University Medical Center, Durham, USA;Department of Surgery, Durham VA Medical Center, Durham, USA;Division of Otolaryngology, Duke University Medical Center, Durham, USA;Duke University School of Medicine, Durham, USA;Department of Surgical Sciences, Duke University Medical Center, Durham, USA

关键词: Immunotherapy;    Tumor;    Dendritic cell;    PC61;    Fusion;    Regulatory T cell;   

Others  :  827401
DOI  :  10.1186/1479-5876-11-148

 received in 2013-02-26, accepted in 2013-06-04,  发布年份 2013

【 摘 要 】

Background

A promising cancer vaccine involves the fusion of tumor cells with dendritic cells (DCs). As such, a broad spectrum of both known and unidentified tumor antigens is presented to the immune system in the context of the potent immunostimulatory capacity of DCs. Murine studies have demonstrated the efficacy of fusion immunotherapy. However the clinical impact of DC/tumor fusion vaccines has been limited, suggesting that the immunosuppresive milieu found in patients with malignancies may blunt the efficacy of cancer vaccination. Thus, novel strategies to enhance fusion vaccine efficacy are needed. Regulatory T cells (Tregs) are known to suppress anti-tumor immunity, and depletion or functional inactivation of these cells improves immunotherapy in both animal models and clinical trials. In this study, we sought to investigate whether functional inactivation of CD4+CD25+FoxP3+ Treg with anti-CD25 monoclonal antibody (mAb) PC61 prior to DC/tumor vaccination would significantly improve immunotherapy in the murine B16 melanoma model.

Methods

Treg blockade was achieved with systemic PC61 administration. This blockage was done in conjunction with DC/tumor fusion vaccine administration to treat established melanoma pulmonary metastases. Enumeration of these metastases was performed and compared between experimental groups using Wilcoxon Rank Sum Test. IFN-gamma ELISPOT assay was performed on splenocytes from treated mice.

Results

We demonstrate that treatment of mice with established disease using mAb PC61 and DC/tumor fusion significantly reduced counts of pulmonary metastases compared to treatment with PC61 alone (p=0.002) or treatment with control antibody plus fusion vaccine (p=0.0397). Furthermore, IFN-gamma ELISPOT analyses reveal that the increase in cancer immunity was mediated by anti-tumor specific CD4+ T-helper cells, without concomitant induction of CD8+ cytotoxic T cells. Lastly, our data provide proof of principle that combination treatment with mAb PC61 and systemic IL-12 can lower the dose of IL-12 necessary to obtain maximal therapeutic efficacy.

Conclusions

To our knowledge, this is the first report investigating the effects of anti-CD25 mAb administration on DC/tumor-fusion vaccine efficacy in a murine melanoma model, and our results may aide the design of future clinical trials with enhanced therapeutic impact.

【 授权许可】

   
2013 Tan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15:138-47.
• [2]Curtsinger JM, Lins DC, Mescher MF: Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003, 197:1141-51.
• [3]Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, et al.: Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002, 104:14-20.
• [4]Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, et al.: Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol Basel 2004, 116:169-78. discussion 79–86
• [5]Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, et al.: 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007, 179:4910-8.
• [6]Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et al.: PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009, 182:5240-9.
• [7]Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, Shu S, et al.: Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 2008, 68:4045-9.
• [8]Koido S, Hara E, Homma S, Namiki Y, Ohkusa T, Gong J, et al.: Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol 2009, 2009:657369.
• [9]Sakaguchi S, Sakaguchi N: Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 2005, 24:211-26.
• [10]Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA: CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003, 100:10878-83.
• [11]Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F: An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999, 190:995-1004.
• [12]Paust S, Lu L, McCarty N, Cantor H: Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA 2004, 101:10398-403.
• [13]Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-51.
• [14]Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, et al.: Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007, 446:685-9.
• [15]Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-8.
• [16]Traverso I, Fenoglio D, Negrini S, Parodi A, Battaglia F, Kalli F, et al.: Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. Hum Immunol 2012, 73:207-13.
• [17]Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-33.
• [18]Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, et al.: Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007, 179:4919-28.
• [19]Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-25.
• [20]Kohm AP, McMahon JS, Podojil JR, Begolka WS, DeGutes M, Kasprowicz DJ, et al.: Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 2006, 176:3301-5.
• [21]Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI: Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008, 333:167-79.
• [22]Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, et al.: Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011, 118:3003-12.
• [23]Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, et al.: A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 2012, 7:e31046.
• [24]Goebel J, Stevens E, Forrest K, Roszman TL: Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol 2000, 8:153-9.
• [25]Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, et al.: Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clinical cancer research: an official journal of the American Association for Cancer Research 2006, 12:4294-305.
• [26]Setiady YY, Coccia JA, Park PU: In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Eur J Immunol 2010, 40:780-6.
• [27]Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, et al.: Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010, 16:5067-78.
• [28]Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, et al.: CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999, 96:8633-8.
• [29]Caignard A, Guillard M, Cai Z, Asselin-Paturel C, Carayol G, Chouaib S: The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/Fas-L cytotoxic pathway. Tissue Antigens 1996, 48:295-300.
• [30]Qin Z, Blankenstein T: CD4+ T cell–mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000, 12:677-86.
• [31]Seliger B, Hammers S, Hohne A, Zeidler R, Knuth A, Gerharz CD, et al.: IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 1997, 3:573-8.
• [32]Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998, 188:2357-68.
• [33]Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS: Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004, 228:130-7.
• [34]Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999, 154:745-54.
• [35]Terabe M, Berzofsky JA: The role of NKT cells in tumor immunity. Adv Cancer Res 2008, 101:277-348.
• [36]Indrova M, Bieblova J, Rossowska J, Kuropka P, Pajtasz-Piasecka E, Bubenik J, et al.: HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol 2009, 34:173-9.
• [37]Zheng R, Kjaergaard J, Lee WT, Cohen PA, Shu S: Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. Cancer Treat Res 2007, 135:223-37.
• [38]Car BD, Eng VM, Lipman JM, Anderson TD: The toxicology of interleukin-12: a review. Toxicol Pathol 1999, 27:58-63.